📰 Immune Sciences News
Page 5 - Immune Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immune Sciences. Real-time updates on events, politics, business and more.
April 11, 2024
Asia stocks are mostly lower after gains for Big Tech shares helped U.S. stock indexes claw back much of their slide from the day before. Tokyo and Taiwan rose but
April 11, 2024
Asia stocks are mostly lower after gains for Big Tech shares helped U.S. stock indexes claw back much of their slide from the day before
April 11, 2024
Jumps for Big Tech stocks helped U.S. stock indexes claw back much of their slide from the day before, when worries that interest rates may stay high for a while
April 5, 2024
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) traded down 5.6% on Wednesday . The company traded as low as $36.80 and last traded at $37.02. 583,722 shares were traded during trading, a decline of 48% from the average session volume of 1,126,938 shares. The stock had previously closed at $39.21. Analyst […]
April 3, 2024
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) has been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage […]
April 3, 2024
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the […]
April 1, 2024
-- The Company will present updated data in a late-breaking poster session for povetacicept in IgA nephropathy patients -- -- The Company will host an investor event the same day concurrently with...
March 23, 2024
Oppenheimer restated their outperform rating on shares of Alpine Immune Sciences (NASDAQ:ALPN – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $44.00 price target on the biotechnology company’s stock, up from their previous price target of $33.00. Other research analysts have also issued reports about the […]